Most pharmaceutical manufacturers cannot answer a simple question: does our SOP library fully satisfy current regulatory expectations? The answer requires synthesising thousands of FDA 483 observations, warning letters, guidance documents, ICH guidelines, and EU GMP requirements into a coherent quality standard — then comparing every procedure against it. No quality team can do this manually at scale. Celestara agents ingest the global regulatory landscape, construct an organisation-specific quality benchmark, assess every SOP against it, and proactively monitor new FDA enforcement actions to flag which procedures need attention before inspectors arrive.
Key Highlights
Regulatory Context
The firm lacked SOPs for 100% visual inspection of filled bottles, performed no acceptable quality limit inspections on commercial batches, and had no container closure integrity testing procedures for solution drug products. The AQL SOP required inspections only for incoming materials and investigations — not for finished products. Multiple drug products were manufactured and released without these fundamental quality controls documented in any procedure.
The quality unit had not performed the necessary assessments to ensure objectionable practices did not affect sterile drug product quality. Environmental trend reports for controlled areas and critical utilities were inadequate — a trend assessment document covering hundreds of microbial recoveries failed to provide comprehensive analysis of sampling locations or actions taken to reduce events. Personnel did not demonstrate necessary understanding of cGMP data integrity and sterile manufacturing processes.
The sterile glove leak test SOP did not provide clear instructions for post-integrity testing and lacked quality review requirements — production reports were not reviewed by Quality despite the procedure requiring verification. Separately, operators were neither trained nor provided SOP instructions for collecting in-process samples during end-filling operations, leaving critical sampling activities undocumented and uncontrolled.
The firm's deviation management SOP did not contain instructions for documenting decisions with justification to continue or abort manufacturing after an out-of-specification test result. When an OOS result was obtained during an intermediate processing step, manufacturing was continued with no documentation — either in the deviation report or the batch record — of the justification to proceed. The gap between the SOP and current FDA expectations for OOS decision traceability was not identified until the inspection.
In December 2024, the firm developed a new procedure for qualification of visual inspectors and simultaneously obsoleted the previous protocol-based procedure. However, employees performing visual inspection on sterile drug products were only qualified according to the now-obsolete procedure. As of June 2025, the firm had no employees fully qualified to perform 100% visual inspection activities on sterile products — a gap that persisted for six months without detection or escalation.
Inspectors observed trucks of scrap materials leaving the facility containing torn pieces of GMP documents including analytical balance printouts, signed worksheets with handwritten documentation, and uncontrolled papers with manufacturing and testing information. In the QC laboratory, cleaning personnel were removing scrap bags containing torn analytical printouts, pH meter printouts, and Karl Fisher test equipment printouts. The quality unit had no effective oversight on the control and management of GMP documents critical to ensuring drug product safety.
The Problem
SOP Compliance Gap Assessment in Celestara
Celestara agents ingest the entire FDA enforcement landscape — thousands of 483 observations, warning letters, guidance documents, and industry standards — and synthesise them into a structured, organisation-specific quality standard. This is not a static checklist: the standard encodes what FDA actually cites, how frequently, in what context, and which CFR sections co-occur. The result is a living benchmark that represents current regulatory expectations at the depth required for SOP-level gap assessment.
Celestara ingests your complete SOP repository — regardless of format, age, or document management system — and decomposes every procedure into structured elements: procedural steps, regulatory references, acceptance criteria, roles, training requirements, and system dependencies. This structural decomposition converts narrative SOP content into a format that can be systematically compared against the quality standard, enabling gap detection that goes far beyond keyword matching.
The Gap Assessor agent compares every structured SOP element against the quality standard, identifying three categories of gaps: missing procedures (regulatory requirements with no corresponding SOP), inadequate depth (SOPs that address a topic but lack the specificity FDA expects), and outdated content (SOPs referencing superseded guidance or omitting current expectations). Each gap is scored by citation frequency and regulatory severity, producing a risk-ranked assessment of the entire SOP library.
Celestara continuously monitors new FDA enforcement actions — every new 483 observation, warning letter, and guidance update — and correlates them against your SOP library in real time. When FDA cites a procedural gap at a peer facility, the Regulatory Monitor agent immediately checks whether your SOPs have the same vulnerability. When new guidance shifts inspection priorities, the quality standard is updated and the impact on your SOP coverage is assessed within hours, not months.
Celestara translates every identified gap into a concrete remediation plan: which SOPs need revision, what content must be added or updated, which regulatory requirements the revision satisfies, and how to sequence changes across sites and departments. The Remediation Planner agent drafts specific SOP language changes, new procedural sections, and updated regulatory references — ready for QA review and approval. The roadmap is continuously reprioritised as the quality standard evolves and new gaps are identified.
The Solution
Purpose-built tools that address both the regulatory intelligence gap and the operational barriers to systematic SOP assessment — transforming gap detection from a subjective, experience-dependent exercise into a data-driven, continuously updated process.
Celestara agents synthesise thousands of FDA 483 observations, warning letters, guidance documents, and ICH/EU GMP standards into a structured, organisation-specific quality benchmark. The standard encodes not just what regulations require, but what FDA actually cites — weighted by frequency, severity, and recency. This living model evolves continuously as new enforcement data is published, ensuring your quality benchmark never falls behind current regulatory expectations.
Every SOP in your library is parsed, structured, and compared against the quality standard to identify missing procedures, inadequate depth, and outdated content. Gaps are classified by type and scored by regulatory risk — combining citation probability, operational impact, and time exposure. AI agents generate specific remediation suggestions with draft SOP language that QA teams can review and approve, reducing revision cycles from weeks to days.
Deploy the quality standard consistently across all manufacturing sites with centralised gap tracking, site-level compliance dashboards, and automated propagation of remediation priorities. When a gap is identified at the corporate level, every site receives the same assessment — eliminating inconsistency in SOP coverage that creates audit exposure during multi-site inspections.
FDA Tracker continuously monitors every new 483 observation, warning letter, and guidance document as it is published. When a peer facility is cited for a specific SOP gap, the system immediately checks whether your SOP library has the same vulnerability and alerts your quality team with specific impact analysis — turning industry enforcement actions into proactive intelligence for your own SOP programme.
Results
Projected results from organisations using Celestara for continuous SOP compliance gap assessment against an AI-constructed quality standard
Next Step
Stop discovering SOP gaps on inspection day. Celestara constructs a living global quality standard from FDA enforcement data, compares every procedure in your library against it, and proactively monitors new regulatory actions to flag which SOPs need attention — before auditors find the gaps your annual review missed.
Get Started